ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
![NanoAssemblr® Feature]( "Single-Use System For Clinical And Commercial Production Of LNPs")
Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.
-
![NanoAssemblr®]( "Automated, Single-Use System For Clinical And Commercial LNP Production")
The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Services For Advancing mRNA-LNPs From Bench To Clinic")
Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.
-
![Scientists In Laboratory GettyImages-1140779754]( "Complete Solutions For Every Step Of Pharmaceutical Development")
By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.
-
![Ignite]( "A Disruptive Technology Accelerating Drug Development")
Ignite simplifies the transition into clinical programs by incorporating these fundamental process steps for scale up in the earliest stages of pre-clinical development.
-
![GenVoy-ILM]( "GenVoy-ILM™ T Cell Kit For mRNA, Ignite™")
GenVoy-ILM™ T Cell Kit for mRNA, Ignite is an lipid nanoparticle (LNP) reagent mix optimized for the delivery of messenger RNA (mRNA) or Cas9 mRNA/sgRNA into activated human primary T cells.
-
![Blaze]( "A Next-Generation Technology For The Power To Scale")
With NxGen™ technology on the NanoAssemblr® Blaze™, important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
-
![1]( "T Cell Kit For mRNA On NanoAssemblr Spark")
The GenVoy-ILM T Cell Kit for mRNA is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr Spark instrument and cartridges.
-
![GMP]( "NanoAssemblr® GMP System: Power To Commercialize")
Built on our revolutionary NxGen™ technology found in our NanoAssemblr® family of instruments, the NanoAssemblr® GMP System enables you to go from concept to clinic with speed and confidence.
-
![Genvoy]( "GenVoy-ILM™: Power To Explore")
GenVoy-ILM is a pre-optimized lipid mixture designed to encapsulate RNA – mRNA, gRNA, siRNA, miRNA, tRNA – in LNP.
-
![Spark]( "NanoAssemblr® Spark™: Freedom To Discover")
The NanoAssemblr® Spark™ is ideal for nanomedicine formulation discovery and screening at microliter scales.
WEBINARS AND PODCASTS
APPLICATION NOTES
- How To Successfully Isolate Your T Cells
- Exosome Isolation By TFF And Size Exclusion Chromatography
- Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges
- Understanding The Microfluidic Platforms For Scaling Nanoparticle Production
- Low-Volume Production For Screening High-Value Nanoparticle Materials
- Genome Editing of Human Primary T Cells With Lipid Nanoparticles
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
![GettyImages-2151198847-lipid-nanoparticle-with-rna-strands]( "Advancing Cell Therapies With Lipid Nanoparticles")
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
![GettyImages-1914829121-rna-strands-molecule]( "Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines")
Discover how self-replicating RNA (srRNA) can revolutionize vaccine development with sustained protein expression, lower doses, and fewer side effects to advance next-gen RNA therapeutics.
-
![Outsourcing RNA Feature Image]( "Outsourcing RNA-LNP Production: A Key To Competitive Success")
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
-
![Embracing Ongoing Process Verification in Cleaning Validation]( "Toward A Gene Therapy Platform: What's The Best Format Of TFF?")
Evaluate tangential flow filtration (TFF) formats and membrane chemistries for AAV gene therapy processing, assessing performance, scalability, economy, and closed processing options.
-
![GettyImages-183281520-plastic resins-polymer]( "Solvent-Free Purification Of D84-mer Oligonucleotide Using Capto™ PlasmidSelect Resin")
Discover a solvent-free process using Capto PlasmidSelect and Capto Q ImpRes resins. They enable high-purity, scalable purification of long oligonucleotides, achieving more than 95% of full-length product purity.
-
![GettyImages-1355122387 RNA]( "Single-Step Purification Of A 21-mer Oligonucleotide Using Capto™ Q ImpRes Resin")
Explore how the oligonucleotide therapeutics market is advancing with scalable solutions for high-purity purification, supporting global production of life-changing RNA therapies.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "The Crucial Role Of Downstream Processing In Optimizing RNA-LNP Drug Development")
Explore the key aspects of lipid nanoparticle (LNP) development, including the essential downstream processes of Tangential Flow Filtration (TFF) and normal flow filtration.
-
![GettyImages-1319439243-dna-gene-therapy-helix]( "Genomic Medicine Demands Manufacturing Innovation")
The promise of novel therapeutic modalities can only be realized when effective science is paired with efficient manufacturing to provide cost-effective therapies to patients in need.
-
![Laboratory-analysis-GettyImages-1385463753]( "Tips For Viral Vector Production")
Learn about how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.
-
![GettyImages-1297146235-dna]( "A Scalable Single-Use Two-Step pDNA Purification Process")
Evaluate the performance of a single-use two-step plasmid purification process, and see how it compares to the existing three-step purification method.
